HARVARD BIOSCIENCE INC
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our facilities incorporate manufacturing, research and development, sales and marketing, and administration functions. As of December 31, 2025, we leased the following principal facilities:
| Approximate | |||
|---|---|---|---|
| Location | Description of Facility | Square Footage | Expiration |
| New Brighton, Minnesota | Manufacturing facility | 75,000 | 2030 |
| Holliston, Massachusetts | Manufacturing facility and corporate headquarters | 52,000 | 2029 |
| Reutlingen, Germany | Manufacturing facility | 23,000 | 2029 |
| Barcelona, Spain | Manufacturing facility | 16,000 | 2026+ |
| March-Hugstetten, Germany | Manufacturing facility | 11,000 | 2029 |
- This lease is renewed on a month-to-month basis.
We also lease facilities in Cambridge, England; Stockholm, Sweden; Beijing, China; and Shanghai, China. As described elsewhere in this report, as part of Project Viking, the Company expects to close its manufacturing facility in Holliston, MA and transition U.S. production to its manufacturing hub in Minneapolis, MN. Certain operations are expected to be relocated to facilities in Germany, Sweden, and the UK, aligning specific product lines with their designated center of excellence and most strategically advantageous logistical location. We believe our current facilities are adequate for our needs for the foreseeable future.
**Item 3.*****Legal Proceedings.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.